EKF has delivered a FY’19 revenue and EBITDA performance in line with the market’s recently upgraded expectations. Cash generation remains strong in H2, and the company continues to gain momentum delivering its strategic goals. The outlook for 2020 remains positive with development initiatives carried out in recent periods expected to start to bear fruit towards the end of the year. Further upside is expected due to, amongst other things, the launch of the Glycated Albumin test, t
29 Jan 2020
Trading statement confirms upgraded FY’19 performance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Trading statement confirms upgraded FY’19 performance
EKF Diagnostics Holdings plc (EKF:LON) | 28.1 0 0.4% | Mkt Cap: 127.5m
- Published:
29 Jan 2020 -
Author:
Chris Glasper -
Pages:
3
EKF has delivered a FY’19 revenue and EBITDA performance in line with the market’s recently upgraded expectations. Cash generation remains strong in H2, and the company continues to gain momentum delivering its strategic goals. The outlook for 2020 remains positive with development initiatives carried out in recent periods expected to start to bear fruit towards the end of the year. Further upside is expected due to, amongst other things, the launch of the Glycated Albumin test, t